Moderna (NASDAQ: MRNA) has been on fire this year, with the biotech's shares up by 39% through Feb. 6. This isn't due to the ...

Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on ...

Gilead's revenue is anchored by Biktarvy, protected by exclusivity through 2036, reducing near-term patent cliff risk vs. peers. Learn more about GILD stock here.

U.S. equity markets continue to march higher and at Goodreid our view remains unchanged. We believe that the cyclical bull market that started in October 2022 is still underway and returns in 2026 ...

Exelixis, Inc. today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, ...

Looking for broad exposure to the Small Cap Value segment of the US equity market? You should consider the JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), a passively managed exchange traded ...

AbbVie’s latest agreement with the Trump administration underscores a major shift in US drug pricing policy, one in which domestic manufacturing is no longer a peripheral concern but it is built into ...

HPV, or human papillomavirus, is linked to several types of cancer, including cervical, anal, and throat cancers. India’s HPV vaccine market was worth ₹91 crore as of January 2026, on a moving annual ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

Eli Lilly LLY announced that it entered a definitive agreement to acquire the privately held clinical-stage biotech Orna Therapeutics in a deal valued at $2.4 billion. This transaction includes both ...

J&J lost U.S. patent exclusivity of Stelara in 2025. According to patent settlements and license agreements, Amgen AMGN, Teva ...